Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.
- Exclusive two-year Felix™ agreement in Poland
- Minimum contracted value of A$350,000
- Poland becomes third European market for Felix™
- Three-month evaluation period precedes recurring orders
- New European Director to support sales expansion
Poland Joins European Felix™ Network with Exclusive Deal
Memphasys Limited (ASX:MEM) has taken a decisive step in its European commercial rollout by signing an exclusive two-year commercialisation agreement with Warsaw-based TK Biotech for its Felix™ sperm separation system. The deal, valued at approximately A$350,000 (€212,000) over the contract term, positions Poland as the third European market, after Italy and the UK, where Felix™ has secured commercial sales or partnerships following CE Mark approval.
Structured Rollout with Evaluation Phase and Recurring Revenue
The agreement kicks off with a three-month evaluation period, during which TK Biotech will place an initial order to facilitate product training, clinic demonstrations, and early market introduction. Upon successful completion, quarterly minimum purchase commitments commence immediately, scaling up notably in the second year. This phased approach provides a clear path to recurring revenue, with the first evaluation order expected to be invoiced in the September quarter and minimum quarterly orders starting December 2026.
Poland’s IVF Market Ripe for Innovation
Poland’s IVF sector has been expanding rapidly, buoyed by a government-funded IVF program launched in June 2024. As of May 2026, the program has engaged 58 fertility clinics, supported over 51,000 couples, and contributed to nearly 30,000 clinical pregnancies. This public funding and accessibility create a fertile environment for reproductive technologies like Felix™ that promise improved clinical outcomes and workflow efficiencies. TK Biotech’s established IVF portfolio and technical service network across Poland provide a strong platform for Felix™’s commercial introduction.
Local Partner Model and European Sales Leadership
Under the agreement, TK Biotech will handle local importer, distributor, and supply chain responsibilities, alongside product demonstrations, training, and first-line customer support. Memphasys will back these efforts with technical support, marketing materials, and direct involvement in key clinical engagements. To accelerate European growth, Memphasys has appointed a Director of Commercial Operations – Europe, expected to start mid-September 2026, tasked with driving sales, partner onboarding, and client management across the continent.
Momentum Builds Across Europe and Beyond
This Polish agreement follows a string of recent commercial advances including UK market traction and Southeast Asian deals, reflecting Memphasys’ strategy to convert inbound interest into contracted partnerships and recurring revenues. With Felix™ gaining footholds in multiple IVF markets, the company’s near-term focus remains on converting ongoing evaluations and late-stage contract negotiations into sales. The coming quarters will be critical in demonstrating the scalability of Felix™’s commercial model beyond its initial European strongholds.
Bottom Line?
Memphasys’ Polish deal consolidates its European expansion, but converting evaluation phases into sustained sales will be key to unlocking Felix™’s growth potential.
Questions in the middle?
- Will TK Biotech meet or exceed the minimum purchase commitments to sustain exclusivity?
- How quickly can Memphasys convert other European and international IVF markets into recurring revenue streams?
- What impact will the new European Director have on accelerating partner onboarding and sales conversion?